{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009225","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.067315+00:00","generated_at":"2026-06-01T04:08:49.420964+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aprea Therapeutics doses first patient in Phase 1 trial of oral WEE1 inhibitor APR-1051","bullets":["First patient dosed in ACESOT-1051 Phase 1 trial of oral WEE1 inhibitor APR-1051 as monotherapy in advanced solid tumors.","APR-1051 is a potent, highly selective WEE1 inhibitor designed to limit off-target PLK inhibition and improve PK profile.","Trial targets tumors with CCNE1/2 amplification, FBXW7/PPP2R1A mutations, KRAS-G12/TP53 co-mutated CRC, or uterine serous carcinoma.","Dose escalation (up to 39 patients) and dose optimization (up to 40 patients) to determine RP2D; first site at NEXT Oncology (San Antonio).","Company expects clinical update by year-end 2024 and preliminary efficacy data in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009225","json":"https://secwatch.observer/filing/0001558370-24-009225.json","markdown":"https://secwatch.observer/filing/0001558370-24-009225.md","text":"https://secwatch.observer/filing/0001558370-24-009225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024009225/0001558370-24-009225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024009225/apre-20240617x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:08:49.420964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}